Allink Biotherapeutics
Allink Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics. The company is advancing its global Phase I/II clinical programs and expanding its global footprint, aiming to innovate in the field of targeted cancer therapies.
Leadership & Board
- Current Number of Employees
- 9
- Current LinkedIn Followers
- 304
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $131M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $89M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Employee Trend
Allink Biotherapeutics had 9 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
9Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Allink Biotherapeutics had 304 followers as of October 12, 2026. The number of followers increased by 1 (0.33%) week-over-week.
304Latest Followers Count
1(0.33%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 16, 2025 | Series A | $89.00M | ― |
| Dec 28, 2024 | Series A | $42.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Lanchi Ventures | Series A (2) |
| 5Y Capital | Series A |
| Yuanbio Venture Capital | Series A |
| Legend Capital | Series A |
| Lapam Capital | Series A |
| Meituan Long-Z Investment | Series A |
| Runzhang Venture Capital | Series A |
Similar Companies
A snapshot of private companies similar to Allink Biotherapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
